Mark Auerbach

Mark Auerbach, was formerly a director for virology biotech Assembly Biosciences (NASDAQ:ASMB), serving as chairman of the audit committee and a member of the compensation committee. He was also lead independent director and chairman of the audit committee of Optimer Pharmaceuticals, a public company, until its acquisition by Cubist Pharmaceuticals, as well as Chairman of Neuro-Hitech, an early-stage pharmaceutical developer. Over the last 20 years, Mr. Auerbach also has served as a director for several other companies, including Par Pharmaceutical Companies, Inc., a publicly traded manufacturer and marketer of generic pharmaceuticals and the parent of Par Pharmaceutical, Inc. Earlier in his career Mark served as Chief Financial Officer of Central Lewmar, a national fine paper distributor. He received a BS in Accounting from Rider University.